@article {Phipps2020.05.15.20103580, author = {William S. Phipps and Jeffrey A. SoRelle and Quan-Zhen Li and Lenin Mahimainathan and Ellen Araj and John Markantonis and Chantale Lacelle and Jyoti Balani and Hiren Parikh and E. Blair Solow and David R. Karp and Ravi Sarode and Alagarraju Muthukumar}, title = {SARS-CoV-2 Antibody responses do not predict COVID-19 disease severity}, elocation-id = {2020.05.15.20103580}, year = {2020}, doi = {10.1101/2020.05.15.20103580}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Initial reports indicate adequate performance of some serological-based SARS-CoV-2 assays. However, additional studies are required to facilitate interpretation of results, including how antibody levels impact immunity and disease course.Methods In this study, a total of 968 subjects were tested for IgG antibodies reactive to SARS-CoV-2. We confirmed analytic specificity using 656 plasma samples from healthy donors, 49 sera from patients with rheumatic disease, and 90 specimens from individuals positive for PCR-based respiratory viral panel. One-hundred seventy-three cases of confirmed or suspected SARS-CoV-2 were tested for IgG. A subgroup of 37 SARS-CoV-2 PCR-positive cases was tested for nucleocapsid-specific IgM antibody using an in-house developed microarray method. Antibody levels were compared between disease severity groups.Results All specificity specimens were negative for SARS-CoV-2 IgG antibodies (0/656, 0\%). Cross reactivity was not detected in specimens with antinuclear antibodies and rheumatoid factor, or cases with previous diagnosis of viral infection including human coronavirus. Positive agreement of IgG with PCR was 83\% of samples confirmed to be more than 14 days from symptom onset, with less than 100\% sensitivity attributable to a case with severe immunosuppression. Virus-specific IgM was positive in a higher proportion of cases less than 3 days from symptom onset. No association was observed between mild and severe disease course with respect to IgG and IgM levels.Conclusions The studied SARS-CoV-2 IgG assay had 100\% specificity and no adverse cross-reactivity. Index values of IgG and IgM antibodies did not predict disease severity in our patient population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary material.}, URL = {https://www.medrxiv.org/content/early/2020/05/18/2020.05.15.20103580}, eprint = {https://www.medrxiv.org/content/early/2020/05/18/2020.05.15.20103580.full.pdf}, journal = {medRxiv} }